NJ
NJ Addiction Centers
Mental_health_dual_diagnosis

Dual Diagnosis and Co-Occurring Mental Health Disorders

By NJ Addiction Centers Editorial Team | Last reviewed: | 14 min read Clinically Reviewed

Dual Diagnosis and Co-Occurring Mental Health Disorders

Roughly half of all people with a substance use disorder also have a diagnosable mental health condition. According to SAMHSA’s 2023 National Survey on Drug Use and Health, approximately 21.5 million adults in the United States had both a substance use disorder and a mental illness in the past year. When addiction and a psychiatric condition exist simultaneously, clinicians refer to this as a dual diagnosis or co-occurring disorder. Treatment that addresses only the addiction or only the mental health condition — but not both — is associated with poorer outcomes and higher relapse rates. This guide explains how co-occurring disorders develop, which conditions most frequently overlap with substance use, and how integrated treatment works in New Jersey.

Key Takeaways

  • Dual diagnosis means a person has both a substance use disorder and a mental health condition. Neither condition is secondary — both require treatment.
  • Depression, anxiety disorders, PTSD, ADHD, and bipolar disorder are the mental health conditions most commonly found alongside addiction.
  • Integrated treatment — addressing both conditions simultaneously with a coordinated clinical team — produces better outcomes than treating each condition separately.
  • New Jersey operates MICA (Mentally Ill Chemically Addicted) programs that provide specialized integrated care for people with co-occurring disorders.
  • Screening for co-occurring conditions at intake is considered a clinical standard; untreated mental health conditions are a leading driver of relapse.

What Is Dual Diagnosis?

Dual diagnosis: A clinical term indicating that a person meets diagnostic criteria for both a substance use disorder and at least one independent mental health disorder. The two conditions may interact — each worsening the other — but they are distinct diagnoses that require their own treatment approaches.

The concept is straightforward, but the clinical reality is complex. Mental health conditions and substance use disorders share overlapping neurobiology (both involve dysregulation in dopamine, serotonin, and stress-response systems), overlapping risk factors (trauma, genetic vulnerability, adverse childhood experiences), and overlapping symptoms (sleep disruption, irritability, impaired functioning). This overlap makes accurate diagnosis difficult, particularly during active substance use when substance-induced symptoms can mimic primary psychiatric disorders.

Prevalence data. SAMHSA’s most recent national survey data indicate that among adults with a substance use disorder, approximately 38 percent also have a mental illness. Among those with a serious mental illness, approximately 25 percent have a co-occurring substance use disorder. These numbers suggest that co-occurrence is the rule rather than the exception in clinical treatment settings.

Why integration matters. Historically, addiction treatment and mental health treatment operated in separate systems — different facilities, different providers, different funding streams. A person with depression and alcohol use disorder might see an addiction counselor who does not treat depression and a psychiatrist who does not address alcohol use. Research published in the Journal of the American Medical Association and subsequent meta-analyses have demonstrated that integrated treatment — where both conditions are addressed by the same clinical team using coordinated treatment plans — produces significantly better outcomes than parallel or sequential treatment models.

In New Jersey, the Division of Mental Health and Addiction Services (DMHAS) oversees both mental health and substance use treatment systems, which has facilitated the development of integrated programming. NJ MICA programs (Mentally Ill Chemically Addicted) are specifically designed to serve individuals with co-occurring disorders in residential and outpatient settings.

Diagnostic Challenges

Accurate dual diagnosis requires a clinician who can distinguish between substance-induced psychiatric symptoms and independent psychiatric disorders. For example:

  • Cocaine and methamphetamine use can produce symptoms that mimic bipolar mania or psychosis
  • Alcohol withdrawal can produce anxiety symptoms indistinguishable from generalized anxiety disorder
  • Opioid withdrawal commonly produces depressive symptoms that may resolve without antidepressant treatment

The clinical standard is to establish a period of abstinence (typically two to four weeks) before making a definitive psychiatric diagnosis, though this is not always practical — and withholding psychiatric treatment during that period may not be clinically appropriate. Experienced dual diagnosis providers use longitudinal assessment, collateral information from family members, and careful history-taking to differentiate primary psychiatric conditions from substance-induced states.

Common Co-Occurring Disorders

Certain mental health conditions appear alongside substance use disorders at rates far above what chance alone would predict. The following conditions have the strongest research-supported links to addiction.

Depression and Substance Use Disorder

Major depressive disorder (MDD) is one of the most common co-occurring conditions. The relationship is bidirectional: depression increases the risk of developing a substance use disorder (often through self-medication), and chronic substance use can induce or worsen depressive episodes through neurochemical changes.

Key clinical considerations:

  • Alcohol is a central nervous system depressant that can worsen depression even while temporarily relieving anxiety
  • Stimulant withdrawal (cocaine, methamphetamine) commonly produces severe depressive symptoms that can be difficult to distinguish from primary MDD
  • Antidepressant medications (SSRIs, SNRIs) remain effective in people with co-occurring substance use disorders, though response rates may be somewhat lower
  • Untreated depression is among the most frequently cited reasons for relapse after substance use treatment

Anxiety Disorders and Substance Use Disorder

Generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder frequently co-occur with substance use — particularly with alcohol, benzodiazepines, and cannabis. Many individuals with anxiety disorders describe their substance use as beginning as an attempt to manage intolerable anxiety symptoms.

The self-medication cycle is particularly dangerous with benzodiazepines and alcohol because these substances directly enhance GABA activity, providing rapid anxiety relief followed by rebound anxiety as the effect wears off. This creates a neurochemical trap: the substance that provides short-term relief simultaneously worsens the underlying condition. For more on this mechanism, see our guide on benzodiazepine addiction.

PTSD and Substance Use Disorder

Post-traumatic stress disorder and addiction share a well-documented relationship. According to the U.S. Department of Veterans Affairs, approximately 46 percent of individuals who meet criteria for PTSD also meet criteria for a substance use disorder. The rates are higher among combat veterans, survivors of sexual assault, and people who experienced childhood abuse.

Substances are commonly used to manage PTSD symptoms: alcohol to dampen hyperarousal, opioids to numb emotional pain, stimulants to combat the fatigue associated with chronic hypervigilance. Effective treatment for PTSD-SUD typically involves trauma-focused therapies (prolonged exposure, cognitive processing therapy, or EMDR) delivered alongside addiction treatment — not after it.

ADHD and Addiction

Attention-deficit/hyperactivity disorder is a significant and frequently overlooked risk factor for substance use disorders. Research published in the journal Biological Psychiatry found that individuals with ADHD are approximately twice as likely to develop a substance use disorder compared to those without ADHD. The connection involves both neurobiology (ADHD involves dysregulated dopamine signaling, as does addiction) and behavioral factors (impulsivity, poor executive function, sensation-seeking).

Stimulant medications prescribed for ADHD (methylphenidate, amphetamine salts) are themselves controlled substances, creating a clinical challenge: the medication that most effectively treats ADHD is pharmacologically related to drugs of abuse. However, multiple longitudinal studies have found that treating ADHD with appropriate medication actually reduces the risk of developing a substance use disorder — untreated ADHD carries a higher addiction risk than medicated ADHD.

For a deeper look at the ADHD-addiction connection and treatment approaches, see our dedicated guide: ADHD and Addiction.

Bipolar Disorder and Substance Use

Bipolar disorder has one of the highest rates of co-occurring substance use among all psychiatric conditions. According to NIDA, approximately 40 percent of individuals with bipolar I disorder and 20 percent of those with bipolar II disorder will develop a substance use disorder at some point. Substance use during manic episodes is particularly common — the impulsivity and grandiosity of mania combine with reduced judgment to drive high-risk behavior including drug and alcohol use.

Alcohol, cannabis, and stimulants are the substances most frequently misused by individuals with bipolar disorder. Treatment requires careful medication management because some substances commonly used in addiction treatment (including certain antidepressants) can destabilize bipolar symptoms. Mood stabilizers (lithium, valproate, lamotrigine) and atypical antipsychotics form the pharmacological foundation for dual diagnosis treatment in this population.

For the complete picture on bipolar-SUD overlap, read: Bipolar Disorder and Substance Abuse.

Personality Traits and Addiction

Beyond the major psychiatric diagnoses, certain personality patterns and conditions interact with substance use in clinically meaningful ways.

Obsessive-compulsive disorder (OCD) and substance use co-occur more frequently than the general population baseline. Some individuals use substances to manage the distress of obsessive thoughts or compulsive rituals. Treatment must be carefully sequenced because some substances (particularly alcohol and benzodiazepines) can interfere with the effectiveness of exposure and response prevention (ERP), the gold-standard therapy for OCD.

Narcissistic personality patterns and substance use share a complex relationship. Research has examined how grandiosity, entitlement, and impaired empathy interact with addiction development and treatment engagement. These personality features can complicate group therapy dynamics and therapeutic alliance — but they do not preclude effective treatment.

The broader category of personality disorders — including borderline personality disorder, which has a co-occurrence rate with substance use disorders estimated at 50 to 70 percent — represents a significant clinical population. Dialectical behavior therapy (DBT), originally developed for borderline personality disorder, has become a standard treatment modality for co-occurring personality disorders and substance use.

For a research-based exploration of how personality traits and conditions intersect with addiction, see our guide on OCD, narcissism, and personality-linked addiction risk.

Substance Use During Pregnancy

Substance use during pregnancy presents unique clinical and ethical considerations. Neonatal abstinence syndrome (NAS) — a withdrawal syndrome in newborns whose mothers used opioids or other substances during pregnancy — affects thousands of infants annually in the United States. According to CDC data, the incidence of NAS increased approximately fivefold between 2004 and 2014.

Pregnant individuals with substance use disorders face significant barriers to treatment, including stigma, fear of legal consequences, and a shortage of treatment programs designed to serve pregnant women. Clinical guidelines from ACOG (the American College of Obstetricians and Gynecologists) recommend medication-assisted treatment with buprenorphine or methadone for pregnant individuals with opioid use disorder — abrupt opioid discontinuation during pregnancy carries risks to both the mother and the fetus.

New Jersey has treatment facilities that specifically serve pregnant women with substance use disorders, including programs that provide prenatal care integrated with addiction treatment. NJ law includes certain protections for pregnant individuals seeking substance use treatment to reduce barriers related to fear of child welfare involvement.

For detailed information on treatment options, NAS, and NJ-specific resources, see: Substance Use During Pregnancy.

Addiction in Special Populations

Certain populations face unique challenges in accessing and benefiting from dual diagnosis treatment.

Older Adults

Substance use disorders in adults over 65 are significantly underdiagnosed and undertreated. According to SAMHSA, the number of adults aged 65 and older with substance use disorders is projected to grow substantially as the baby boomer generation ages. Benzodiazepine dependence is particularly common in this population — often developing from long-term prescribed use for insomnia or anxiety. Additionally, age-related changes in metabolism, increased medication interactions, and cognitive decline complicate both diagnosis and treatment.

LGBTQ+ Communities

LGBTQ+ individuals experience higher rates of substance use and mental health conditions compared to the general population. Research from the Williams Institute at UCLA has documented elevated rates of alcohol use disorder, tobacco use, and illicit drug use among LGBTQ+ populations, driven in part by minority stress, discrimination, family rejection, and barriers to affirming healthcare.

New Jersey has treatment programs that provide affirming care for LGBTQ+ individuals, though availability varies by region. Effective dual diagnosis treatment for this population requires clinicians who understand the specific stressors these communities face and can integrate that understanding into treatment planning.

For more on treatment considerations for these populations, see: Addiction in Older Adults and LGBTQ+ Communities.

Evidence-Based Therapies for Dual Diagnosis

Treating co-occurring disorders requires a clinical approach that can address both the addiction and the psychiatric condition through a unified framework.

Integrated Treatment Models

Integrated dual disorder treatment (IDDT) is an evidence-based model developed by Dartmouth Medical School that combines psychiatric services, substance use treatment, and rehabilitation services into a single, coordinated program. IDDT uses a stages-of-change framework and does not require abstinence as a precondition for psychiatric treatment (or vice versa).

Seeking Safety is a manualized therapy designed specifically for co-occurring PTSD and substance use disorder. It focuses on establishing safety (physical, emotional, relational) as a foundation for recovery from both conditions simultaneously.

Specific Therapeutic Modalities

Dialectical behavior therapy (DBT) was originally developed for borderline personality disorder but has demonstrated effectiveness for a range of co-occurring conditions. DBT’s four skill modules — mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness — address core deficits that drive both psychiatric symptoms and substance use. Programs that have adapted DBT for dual diagnosis populations report improvements in treatment retention, substance use outcomes, and psychiatric symptom management.

Cognitive behavioral therapy (CBT) remains the most broadly applicable evidence-based therapy for both substance use disorders and most psychiatric conditions. Integrated CBT protocols address both conditions by identifying shared cognitive distortions and developing coping strategies that serve dual recovery.

Medication management is a critical component of dual diagnosis treatment. Psychiatric medications (antidepressants, mood stabilizers, antipsychotics, non-benzodiazepine anxiolytics) must be selected with attention to their interaction with substance use. Medications used in addiction treatment (buprenorphine, naltrexone, acamprosate) must be compatible with psychiatric medications the person is taking. This coordination requires prescribers with expertise in both pharmacological domains.

For a focused look at how DBT is applied in dual diagnosis settings, see: DBT for Mental Health and Co-Occurring Disorders.

Frequently Asked Questions

What is the difference between dual diagnosis and co-occurring disorders? The terms are used interchangeably in most clinical and insurance contexts. “Dual diagnosis” is the more commonly recognized term among the general public, while “co-occurring disorders” is preferred in clinical literature because it avoids implying that there are only two conditions present (a person may have multiple co-occurring conditions).

Can I be treated for addiction if I take psychiatric medication? Yes. Modern integrated treatment programs coordinate addiction care and psychiatric medication management. Taking an antidepressant, mood stabilizer, or ADHD medication does not disqualify someone from addiction treatment. In fact, discontinuing psychiatric medication without medical guidance is associated with worse addiction treatment outcomes.

How do I know if I have a co-occurring disorder? Comprehensive screening at treatment intake should assess for both substance use disorders and mental health conditions. Standardized screening tools (such as the PHQ-9 for depression, the GAD-7 for anxiety, and the PC-PTSD-5 for PTSD) are commonly used alongside substance use assessments. If a treatment program does not screen for mental health conditions at intake, this is a red flag regarding the quality of care.

What is a MICA program in NJ? MICA stands for Mentally Ill Chemically Addicted. In New Jersey, MICA programs are specialized residential or outpatient treatment programs designed for individuals with co-occurring serious mental illness and substance use disorders. These programs have staff trained in both psychiatric and addiction treatment and provide integrated care.

Does insurance cover dual diagnosis treatment? Under the Mental Health Parity and Addiction Equity Act, most insurance plans are required to cover mental health and substance use treatment at a level comparable to medical and surgical coverage. In practice, coverage details vary by plan and provider. NJ Medicaid covers dual diagnosis treatment, and many private insurers do as well, though pre-authorization requirements differ.

Is it better to treat the addiction first or the mental health condition first? Research consistently supports treating both conditions simultaneously. Sequential treatment (treating one before the other) was the historical approach but has been shown to produce worse outcomes. Integrated treatment, where both conditions are addressed by a coordinated clinical team, is now the standard of care recommended by SAMHSA and the APA.

Topics in This Guide

This pillar page is part of the Mental Health and Dual Diagnosis content silo on NJ Addiction Centers. For deeper coverage of each topic, explore the dedicated guides below:

For related topics across other silos, see:

Looking for treatment options in your area? We can help point you in the right direction. (800) 555-0199 — or request a callback.